[ad_1] 73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) […]
Tag: Nektar Therapeutics
Nektar Therapeutics Reports Third Quarter 2024 Financial Results
[ad_1] SAN FRANCISCO, Nov. 7, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were […]
Nektar Therapeutics to Participate in Upcoming Investor Conferences
[ad_1] SAN FRANCISCO, Nov. 6, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the upcoming conferences: UBS Global Healthcare Conference in Rancho Palos Verdes, CA on […]
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
[ad_1] SAN FRANCISCO, Oct. 31, 2024 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial markets. Howard […]
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
[ad_1] – New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing specific serum proteins known to be elevated in patients with atopic dermatitis – SAN FRANCISCO, Sept. 25, 2024 […]
